Orchid Pharma Limited
NSE: ORCHPHARMA · Pharmaceuticals · sector
₹818.35NSE close 2026-10-26
Key numbers
Market cap₹4,901 cr
Price₹818.35
52w high / low₹1,144 / ₹480
P/E665.3xSector median 27.9x
P/B3.1xSector median 2.9x
Book value₹261.2
Dividend yield–Sector median 0.48%
ROE0.8%Sector median 11.7%
ROCE1.2%Sector median 12.3%
OPM3.4%Sector median 14.0%
Debt / equity0.19xSector median 0.16x
EV/EBITDA138.6xSector median 18.6x
Interest cover2.1x
Current ratio1.89x
Sales growth 3y+22.8%Sector median +9.6%
Profit growth 3y-40.1%Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹84 cr vs borrowings ₹301 cr (FY26): borrowings are higher by ₹218 cr.
- Operating profit covered interest 2.1x in the last 12 months.
- No promoter shares are pledged.
- Promoter holding rose by 4.61 percentage points in a year, to 74.45% (2026-09-30).
- Operating cash flow was below net profit in 2 of the last 5 years (FY25, FY23).
- Net loss in 2 of the last 8 quarters.
- Revenue was higher than a year earlier in 2 of the last 4 quarters.
- Other income was 242% of net profit in the last 12 months.
- Debtor days went from 87 (FY24) to 113 (FY26).
- No dividend in the last 5 financial years.
- Price ₹818.35 on 2026-10-26: -28.4% from the 52-week high, +70.5% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹1,982.50 · low ₹498.95
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 223 | 217 | 237 | 173 | 194 | 207 | 368 | 304 |
| EBITDA | 30 | 26 | 28 | 14 | -1 | -6 | 30 | 14 |
| OPM % | 13.6% | 12.1% | 11.8% | 8.2% | -0.8% | -2.7% | 8.1% | 4.6% |
| Other income | 8 | 8 | 4 | 11 | 11 | 6 | 8 | 2 |
| Net profit | 27 | 21 | 22 | 15 | -6 | -13 | 26 | 3 |
| EPS (₹) | 5.37 | 4.10 | 4.40 | 2.94 | -1.13 | -2.49 | 4.31 | 0.54 |
| Revenue YoY | -13.1% | -4.6% | +55.1% | +75.9% | ||||
| Profit YoY | -121.0% | -160.7% | +15.9% | -78.4% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 560 | 666 | 819 | 922 | 1,233 | 1,073 |
| EBITDA | 50 | 123 | 111 | 117 | 26 | 37 |
| Net profit | -2 | 46 | 92 | 100 | 10 | 11 |
| EPS (₹) | -0.48 | 11.35 | 19.06 | 19.65 | 1.66 | 1.23 |
| Revenue growth | +19.0% | +23.0% | +12.5% | +33.7% | +26.2% | |
| Profit growth | – | +99.0% | +8.1% | -90.0% | -87.4% | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +22.8% | +22.3% | +26.2% |
| Net profit | -40.1% | – | -87.4% |
| EPS | -47.3% | – | – |
| Share price | – | -17.8% (2y) | +21.5% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 689 | 1,169 | 1,267 | 1,564 |
| Borrowings | – | 331 | 134 | 174 | 301 |
| Cash & equivalents | – | 31 | 267 | 180 | 84 |
| Total assets | – | 1,225 | 1,554 | 1,688 | 2,258 |
| Fixed assets | – | 573 | 619 | 632 | 687 |
| Capital work in progress | – | 46 | 16 | 64 | 341 |
| Investments | – | 44 | 46 | 50 | 67 |
| Receivables | – | 215 | 196 | 242 | 381 |
| Inventory | – | 229 | 264 | 326 | 372 |
| Payables | – | 182 | 230 | 222 | 347 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 89 | 19 | 126 | 19 | 126 |
| Cash from investing | 116 | -31 | -312 | -27 | -277 |
| Cash from financing | -217 | 31 | 167 | 25 | 137 |
| Capex | 14 | 85 | 65 | 150 | 390 |
| Free cash flow | 75 | -66 | 61 | -131 | -264 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 6.7% | 7.9% | 7.9% | 0.6% |
| ROCE % | – | 8.6% | 8.3% | 7.6% | 1.0% |
| Debtor days | – | 118 | 87 | 96 | 113 |
| Inventory days | – | 217 | 199 | 219 | 161 |
| Payable days | – | 173 | 173 | 149 | 150 |
| Cash conversion cycle (days) | – | 162 | 113 | 166 | 124 |
| Working capital days | – | 71 | 236 | 207 | 130 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 74.45% |
| FIIs | 0.93% |
| DIIs | 17.44% |
| of which Mutual funds | 16.88% |
| of which Insurance | 0.01% |
| Public (non-institutions) | 7.18% |
| Quarter | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Aug 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 74.45% | 74.45% |
| Promoter group | % |
|---|---|
| Triveni Trust | 32.62% |
| Manish Dhanuka | 10.94% |
| Pushpa Dhanuka Trust | 9.68% |
| Mamta Dhanuka | 5.20% |
| Arjun Dhanuka | 4.82% |
| UMA Dhanuka | 3.15% |
| Pushpa Dhanuka | 3.09% |
| Varsha Goel | 1.08% |
| Megha Chiripal | 1.08% |
| Manas Dhanuka | 0.58% |
| Harsh Dhanuka HUF | 0.54% |
| Mridul Dhanuka HUF | 0.54% |
| Seema Dhanuka | 0.37% |
| Manish Dhanuka HUF | 0.34% |
| Mahendra Kumar Dhanuka HUF | 0.24% |
| Public holders above 1% | % |
|---|---|
| Quant Mutual Fund - Quant Small CAP Fund | 5.79% |
| Kotak Mahindra Trustee Co Ltd and 6 Others With Same PAN | 3.99% |
| UTI Value Fund and 3 Others With Same PAN | 3.09% |
| Invesco India Contra Fund & 1 Other With Same PAN | 2.41% |
| Bandhan Healthcare Fund & 5 Other With Same PAN | 1.04% |
33,790 shareholders. Pledged: 0.00% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| ORCHPHARMA | ₹4,901 cr | 665.3x | 3.1x | 0.8% | 1.2% | 3.4% | +22.8% | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2023-08-02 | Other | Annual General Meeting |
| 2022-12-22 | Other | Extra Ordinary General Meeting |
| 2022-07-06 | Other | Annual General Meeting |
| 2021-08-04 | Other | Annual General Meeting |
| 2021-06-18 | Other | Extra Ordinary General Meeting |
| 2020-12-21 | Other | Annual General Meeting |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Manufacture of Pharmaceuticals: Manufacture and Sales of Active Pharmaceutical Ingredients and products
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | ORCHPHARMA |
| BSE code | 524372 |
| ISIN | INE191A01027 |
| Face value | ₹10.0 |
| Incorporated | 1992-07-01 |
| Website | www.orchidpharma.com |
| Plants (India / abroad) | 6 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.